Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Slides:

Advertisements

Similar presentations

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.

Advertisements

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

Allogeneic stem cell transplantation for adult Philadelphia chromosome–negative acute lymphocytic leukemia: comparable survival rates but different risk.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Gupta V, Tallman MS, Weisdorf DJ

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How I treat elderly patients with myeloma

Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients.

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience by Régis Peffault.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone by Patrizia Tosi, Elena.

by Michael F. Leahy, and J. Harvey Turner

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.

Biology of Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation

ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission Daniela Damiani,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.

Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Bridge to transplant following Bv+Bs regimen.

Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Biology of Blood and Marrow Transplantation

The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management by Elias J. Anaissie, Tahsine.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

by Jan J. Cornelissen, and Didier Blaise

by Lapo Alinari, and Kristie A. Blum

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Presentation transcript:

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma by Paolo Corradini, Michele Cavo, Henk Lokhorst, Giovanni Martinelli, Carolina Terragna, Ignazio Majolino, Pinuccia Valagussa, Mario Boccadoro, Diana Samson, Andrea Bacigalupo, Nigel Russell, Vittorio Montefusco, Claudia Voena, and Gosta Gahrton Blood Volume 102(5):1927-1929 September 1, 2003 ©2003 by American Society of Hematology

Molecular monitoring of residual myeloma cells after allogeneic stem cell transplantation. Molecular monitoring of residual myeloma cells after allogeneic stem cell transplantation. (A) Cumulative relapse risk according to molecular status. ○ represents PCR-negative patients; ×, PCR-mixed patients; and •, PCR-positive patients. (B) Molecular follow-up. Unique patient numbers are on the left. • indicates PCR-positive; ○, PCR-negative; R, relapse; and ✠, death. Paolo Corradini et al. Blood 2003;102:1927-1929 ©2003 by American Society of Hematology